Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
Pirtobrutinib靶向治疗对伊布替尼耐药的慢性淋巴细胞白血病(CLL)中的BTK C481S突变,但第二位点的BTK突变会导致耐药。
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2022008447
Naeem, Aishath; Utro, Filippo; Wang, Qing; Cha, Justin; Vihinen, Mauno; Martindale, Stephen; Zhou, Yinglu; Ren, Yue; Tyekucheva, Svitlana; Kim, Annette S; Fernandes, Stacey M; Saksena, Gordon; Rhrissorrakrai, Kahn; Levovitz, Chaya; Danysh, Brian P; Slowik, Kara; Jacobs, Raquel A; Davids, Matthew S; Lederer, James A; Zain, Rula; Smith, C I Edvard; Leshchiner, Ignaty; Parida, Laxmi; Getz, Gad; Brown, Jennifer R